405 related articles for article (PubMed ID: 12576168)
1. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy.
Ben-Menachem E; Edrich P; Van Vleymen B; Sander JW; Schmidt B
Epilepsy Res; 2003 Feb; 53(1-2):57-64. PubMed ID: 12576168
[TBL] [Abstract][Full Text] [Related]
2. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
Abou-Khalil B; Hemdal P; Privitera MD
Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
[TBL] [Abstract][Full Text] [Related]
3. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures.
Wu XY; Hong Z; Wu X; Wu LW; Wang XF; Zhou D; Zhao ZX; Lv CZ
Epilepsia; 2009 Mar; 50(3):398-405. PubMed ID: 18657175
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group.
Ben-Menachem E; Falter U
Epilepsia; 2000 Oct; 41(10):1276-83. PubMed ID: 11051122
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study.
Tsai JJ; Yen DJ; Hsih MS; Chen SS; Hiersemenzel R; Edrich P; Lai CW
Epilepsia; 2006 Jan; 47(1):72-81. PubMed ID: 16417534
[TBL] [Abstract][Full Text] [Related]
6. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial.
Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM;
Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886
[TBL] [Abstract][Full Text] [Related]
7. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
Maschio M; Zarabla A; Maialetti A; Fabi A; Vidiri A; Villani V; Giannarelli D
Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy.
Ben-Menachem E; Gilland E
Seizure; 2003 Apr; 12(3):131-5. PubMed ID: 12651076
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial.
Glauser TA; Pellock JM; Bebin EM; Fountain NB; Ritter FJ; Jensen CM; Shields WD
Epilepsia; 2002 May; 43(5):518-24. PubMed ID: 12027913
[TBL] [Abstract][Full Text] [Related]
10. Pregabalin or placebo used adjunctively with levetiracetam in refractory partial-onset epilepsy: a post hoc efficacy and safety analysis in combined clinical trials.
Uthman BM; Almas M; Emir B; Giordano S; Leon T
Curr Med Res Opin; 2011 Jul; 27(7):1285-93. PubMed ID: 21561392
[TBL] [Abstract][Full Text] [Related]
11. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group.
Shorvon SD; Löwenthal A; Janz D; Bielen E; Loiseau P
Epilepsia; 2000 Sep; 41(9):1179-86. PubMed ID: 10999557
[TBL] [Abstract][Full Text] [Related]
12. Levetiracetam in patients with refractory epilepsy: results of the SKATE trial in Austria, Germany and Switzerland.
Steinhoff BJ; Trinka E; Wieser HG;
Seizure; 2005 Oct; 14(7):490-6. PubMed ID: 16169256
[TBL] [Abstract][Full Text] [Related]
13. Long-term levetiracetam treatment of epilepsy patients: clinical audit.
Kuba R; Novotná I; Brázdil M; Kocvarová J; Tyrliková I; Mastík J; Rektor I
Epilepsy Res; 2006 Dec; 72(2-3):111-9. PubMed ID: 16930945
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy.
Grant R; Shorvon SD
Epilepsy Res; 2000 Dec; 42(2-3):89-95. PubMed ID: 11074181
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of levetiracetam (keppra) add-on treatment in adult patients with refractory epilepsy in two tertiary centers].
Auriel E; Chistik V; Blatt I; Margolin N; Neufeld M
Harefuah; 2007 Apr; 146(4):269-71, 318. PubMed ID: 17476932
[TBL] [Abstract][Full Text] [Related]
16. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy.
Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I
Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453
[TBL] [Abstract][Full Text] [Related]
17. Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany.
Opp J; Tuxhorn I; May T; Kluger G; Wiemer-Kruel A; Kurlemann G; Gross-Selbeck G; Rating D; Brandl U; Bettendorf U; Härtel C; Korn-Merker E
Seizure; 2005 Oct; 14(7):476-84. PubMed ID: 16182573
[TBL] [Abstract][Full Text] [Related]
18. Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center.
Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP
Epilepsy Behav; 2007 Mar; 10(2):296-303. PubMed ID: 17317325
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of levetiracetam and topiramate in clinical practice: A head-to-head comparison.
Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP
Seizure; 2008 Jan; 17(1):19-26. PubMed ID: 17618131
[TBL] [Abstract][Full Text] [Related]
20. Behavioral effects and somnolence due to levetiracetam versus oxcarbazepine - a retrospective comparison study of North Indian patients with refractory epilepsy.
Shukla G; Gupta A; Agarwal P; Poornima S
Epilepsy Behav; 2016 Nov; 64(Pt A):216-218. PubMed ID: 27756024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
